Beth Imhoff?Kunsch|Aryeh D. Stein|Reynaldo Martorell|Socorro Parra?Cabrera|Isabelle Romieu|Usha Ramakrishnan
Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial
Nutrition Sciences (Belgium)|Emory University|Nutrition Sciences (Belgium)|Emory University|Nutrition Sciences (Belgium)|Emory University|Instituto Nacional de Salud Pública|Nutrition Sciences (Belgium)|Emory University
longchain polyunsaturated fatty acids docosahexaenoic acid dha influence immune function inflammation however influence maternal dha supplementation infant morbidity unknown investigated effects prenatal dha supplementation infant morbidityin doubleblind randomized controlled trial conducted mexico pregnant women received daily supplementation 400 mg dha placebo 18 22 weeks gestation parturition infants aged 1 3 6 months caregivers reported occurrence common illness symptoms preceding 15 daysdata available 1 3 6 months 849 834 834 infants respectively occurrence specific illness symptoms differ groups however occurrence combined measure cold symptoms lower dha group 1 month 076 95 ci 058100 1 month dha group experienced 26 15 30 shorter duration cough phlegm wheezing respectively 22 longer duration rash p 01 3 months infants dha group spent 14 less time ill p 0001 6 months infants dha group experienced 20 13 54 23 25 shorter duration fever nasal secretion difficulty breathing rash illness respectively 74 longer duration vomiting p 05dha supplementation pregnancy decreased occurrence colds children 1 month influenced illness symptom duration 1 3 6 months